The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.

摘要: Objectives This study sought to assess whether the use of eptifibatide instead abciximab is associated with a difference in outcomes patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Background Pooled data from randomized controlled trials suggest that may be survival advantage PCI acute STEMI. However, large proportion community are treated eptifibatide, an agent shares some but not all pharmacological properties abciximab. Methods We evaluated 3,541 who underwent STEMI October 2002 July 2006 regional consortium and were (n = 729) or 2,812). Results There was no incidence in-hospital death (4.1% vs. 3.5% p 0.39), recurrent (0.8% 1.2%, 0.42), stroke/transient ischemic attack (0.7% 0.6%, 0.80). need blood transfusion (12.4% 11.7%, 0.61), whereas there greater gastrointestinal bleeding (4.8% 2.8%, 0.01). In parsimonious risk-adjusted models, significant between observed respect any measures. Conclusions Currently, used as adjunct antiplatelet majority PCI. apparent early compared